SynAct Pharma’s AP1189 meets primary endpoint and demonstrates favorable safety profile in Rheumatoid Arthritis patients with active joint disease in the Phase 2a BEGIN study
SynAct Pharma AB (“SynAct”) today announced top-line results from the Phase 2a study of AP1189 in early rheumatoid arthritis (RA) patients experiencing severe disease activity. · In this 4-week study, patients treated once-daily with 100 mg AP1189 achieved a significantly greater reduction in mean Clinical Disease Activity Score (CDAI) as compared to placebo. · Change in disease activity from severe to moderate was numerically higher in groups treated with AP1189 as compared to placebo, with the lack of statistical difference likely explained by higher baseline CDAI and inflammation (